We aimed to comprehensively discuss the efficacy and safety of IDH inhibitors in IDH-mutated AML patients by combining the results of our meta-analysis with other current therapeutic agents for IDH-mutated AML patients. This evidence concerns the gene IDH1 and acute myeloid leukemia.